Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Dividends Calendar
    • Research
    • Artikler
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team
Comment: "I can lose everything" – Investors have a taste for risk
Artikel2.5.2025, 10.41 af
Verneri Pulkkinen

Comment: "I can lose everything" – Investors have a taste for risk

Despite the stock market volatility of recent weeks, private investors' risk appetite does not seem to have wavered in the United States, and the dip is being bought by the truckload. Has the risk appetite of young investors changed permanently?

Comment: What if the Fed loses its independence?
Artikel23.4.2025, 07.53 af
Verneri Pulkkinen

Comment: What if the Fed loses its independence?

U.S. President Donald Trump is pressuring Federal Reserve Chairman Jay Powell to cut interest rates, even though the Fed is, by law, an independent entity free from political influence. Next year, Trump will get to appoint a new Fed chair when Powell's term ends. A central bank under the president’s thumb would not restore the market’s waning confidence in U.S. politics. One might ask: Is the U.S. “on the road to Zimbabwe”?

Potential for generous excess returns in Inderes recommendations
Artikel11.4.2025, 15.10 af
Antti Luiro

Potential for generous excess returns in Inderes recommendations

The return of an investment portfolio relative to an index is a simple but brutally honest measure of stock picking success. A similar measure, we believe, will also serve as a tool for assessing the quality and independence of equity research.

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Join Inderes as a full-stack developer
Artikel8.4.2025, 10.42 af
Miikka Laitila

Join Inderes as a full-stack developer

Do you know how to code and are you interested in investing or information democratizing? Join our team to develop the platform, which is used by over 70,000 active investors.

Full-year 2024 results – Q&A
Artikel6.2.2025, 09.51 af
Sampo

Full-year 2024 results – Q&A

Sampo Group sustained strong top-line growth and delivered robust underwriting profit growth in 2024, supported by solid development in all business areas.

Sampo
Sampo’s share split
Artikel5.2.2025, 14.19 af
Sampo

Sampo’s share split

Sampo’s Board has today resolved upon a share split based on the authorisation granted by the Annual General Meeting held on 25 April 2024.

Sampo
CSRD reporting from a stock picker’s perspective: Double materiality assessment
Artikel29.1.2025, 09.14 af
Karoliina Loikkanen

CSRD reporting from a stock picker’s perspective: Double materiality assessment

Double materiality assessment is a tricky term, but in practice it is the point in sustainability reporting where the most relevant issues for the stock picker should be identified.

What a stock picker should understand about the new mandatory corporate sustainability (CSRD) reports, part 1.
Artikel21.1.2025, 11.24 af
Karoliina Loikkanen

What a stock picker should understand about the new mandatory corporate sustainability (CSRD) reports, part 1.

CSRD reports, or sustainability reports, will be part of mandatory annual reporting in the future. The reporting as a whole is very complex, and the aim of this new series of articles is to explain the key aspects of CSRD reporting for stock pickers.

Drug development investment: Value creation through M&As and licensing agreements
Artikel19.12.2024, 11.07 af
Antti Siltanen

Drug development investment: Value creation through M&As and licensing agreements

The fourth part of our series of articles focusing on investing in Life Science companies deals with value creation in drug development companies through M&As and licensing agreements.

Faron PharmaceuticalsHerantis PharmaOrionModulight
January-September 2024 results – Q&A
Artikel6.11.2024, 10.34

January-September 2024 results – Q&A

Sampo Group’s top line growth remained strong and underlying trends positive in January-September 2024, driving underwriting profit growth in a mixed claims environment.   

Sampo
Probabilities of success in drug development
Artikel26.9.2024, 13.26 af
Antti Siltanen

Probabilities of success in drug development

The second part of our series of articles focusing on the basics of investing in Life Science companies deals with the likelihood of successful drug development.

Faron PharmaceuticalsHerantis PharmaMendus
Buy high and sell low
Artikel19.9.2024, 11.58 af
Olli Koponen

Buy high and sell low

Buy low and sell high is the most overused phrase in the investment world. Theoretically, a strategy based on this phrase is probably one of the best investment strategies in hindsight, but often the cheap or expensive nature of a stock or investment can only be determined after the fact.

Clinical phases of drug development
Artikel10.9.2024, 05.42 af
Antti Siltanen

Clinical phases of drug development

We are starting a series of articles focusing on the basics of investing in Life Science companies. This first part of the series describes the clinical phases of drug development that most drug development companies have to go through before they can apply for marketing authorization and commercialize a drug.

Faron PharmaceuticalsHerantis PharmaOrionMendus
Artikel21.8.2024, 06.21

Solar Foods is planning a listing on the Nasdaq First North Growth Market Finland marketplace

The Finnish protein production revolutioniser Solar Foods Oyj (hereinafter “Solar Foods” or “the Company”) is planning a listing and application for admission of shares to trading on the Nasdaq First North Growth Market Finland marketplace maintained by Nasdaq Helsinki Ltd. The planned listing would be carried out in September as a technical listing, i.e. no share issue or sale will be arranged in connection with it.

Solar Foods
January-June 2024 results – Q&A
Artikel7.8.2024, 08.13

January-June 2024 results – Q&A

The first half of 2024 saw continuity of strong top line growth and solid underlying development, supplemented with robust investment returns.

Sampo
Recommended public exchange offer to the shareholders of Topdanmark – Q&A
Artikel17.6.2024, 07.33

Recommended public exchange offer to the shareholders of Topdanmark – Q&A

On 17 June 2024, Sampo and Topdanmark entered into a combination agreement. In this IR blog entry, Sampo address questions shareholders might ask regarding the offer at this point.

Sampo
Stock pickers have had a challenging few years
Artikel14.6.2024, 17.33 af
Verneri Pulkkinen

Stock pickers have had a challenging few years

The point of stock picking is to get better returns than from index funds. If stock picking does not deliver excess returns, the investor always has the option of capturing index returns with a low-cost index fund. As the tech giants have continued their strong rise, their relative weight in equity indices has increased. When a smaller group of stocks drives the index up faster than the rest of the group, it means that more investors are missing out on index returns. Stock picking has worked well in recent years, if it has focused primarily on the largest companies. This may not continue forever, but there are good reasons for this trend.

A look at the lack of new listings
Artikel7.6.2024, 04.44 af
Verneri Pulkkinen

A look at the lack of new listings

As fellow investors will have noticed, Nasdaq Helsinki hasn't seen many new listings for a couple of years. The IPO boom of 2021-22 has been followed by a post-bubble hangover. However, investors can expect further IPOs within a year, unless the economy falters again. 

Small companies crushed on the stock market
Artikel6.6.2024, 04.16 af
Verneri Pulkkinen

Small companies crushed on the stock market

Stock markets around the world are hitting new highs, but for those investing in small companies, the last few years have not been easy. Large companies have dominated the top of the returns lists. It is generally believed that smaller companies, while riskier, can deliver better returns over time because they have more room to grow. But this is not always, if ever, the case.

Scariest graph of the year
Artikel31.5.2024, 05.24 af
Verneri Pulkkinen

Scariest graph of the year

What if China invaded Taiwan? A war would probably lead to a global economic collapse worse than the financial crisis, and there would be no point in owning stocks.

Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Our team
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.